Title: Benartärsjukdom, sekundärprevention - 1177 för vårdpersonal

URL Source: https://vardpersonal.1177.se/kunskapsstod/kliniska-kunskapsstod/benartarsjukdom-sekundarprevention/

**\[1\]**: Sigvant B, Kragsterman B, Falkenberg M, Hasvold P, Johansson S, Thuresson M, et al. Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization. J Vasc Surg. 2016;64(4):1009-17 e3.

**\[2\]**: Sartipy F, Lundin F, Wahlberg E, Sigvant B. Cardiovascular Long-term Outcome and Prophylactic Treatment Patterns in Peripheral Arterial Disease in a Population-based Cohort. Eur Heart J Qual Care Clin Outcomes. 2019

**\[3\]**: Sigvant B, Wiberg-Hedman K, Bergqvist D, Rolandsson O, Andersson B, Persson E, et al. A population-based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences. J Vasc Surg. 2007;45(6):1185-91

**\[4\]**: Pereira Filho AJG, Sartipy F, Lundin F, Wahlberg E, Sigvant B. Impact of Ankle Brachial Index Calculations on Peripheral Arterial Disease Prevalence and as a Predictor of Cardiovascular Risk. Eur J Vasc Endovasc Surg. 2022;64(2-3):217-224

**\[5\]**: Forslund T, Carlsson AC, Ljunggren G, Ärnlöv J, Wachtler C.. Patterns of multimorbidity and pharmacotherapy: a total population cross-sectional study. Fam Pract. 2021;29;38(2):132-140

**\[6\]**: Sigvant B, Wiberg-Hedman K, Bergqvist D, Rolandsson O, Andersson B, Persson E, et al. A population-based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences. J Vasc Surg. 2007;45(6):1185-91

**\[7\]**: Pereira Filho AJG, Sartipy F, Lundin F, Wahlberg E, Sigvant B. Impact of Ankle Brachial Index Calculations on Peripheral Arterial Disease Prevalence and as a Predictor of Cardiovascular Risk. Eur J Vasc Endovasc Surg. 2022;64(2-3):217-224

**\[8\]**: Steg PG, Bhatt DL, Wilson PWF, D´Agostino Sr R, Ohman EM, Röther J, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. J Am Med Assoc 2007;297:1197-206.

**\[9\]**: Baubeta Fridh E, Andersson M, Thuresson M, Sigvant B, Kragsterman B, Johansson S, et al. Amputation rates, mortality, and pre-operative comorbidities in patients revascularised for intermittent claudication or critical limb ischaemia: A population based study. Eur J Vasc Endovasc Surg 2017; 54: 480-86.

**\[10\]**: Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, Fleisher LA, Fowkes FG, Hamburg NM, Kinlay S, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e726–e779.

**\[11\]**: Heald CL,  Fowkes FGR,  Murray GD,  Price JF, Ankle Brachial Index Collaboration. Risk of mortality and cardiovascular disease associated with the ankle-brachial index: Systematic review. Atherosclerosis 2006;189:61-9.

**\[12\]**: Fowkes FG, Murray GD, Butcher I, Heald CL, Lee RJ, Chambless LE, Folsom AR, Hirsch AT, Dramaix M, deBacker G, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA 2008;300:197–208.

**\[13\]**: Criqui MH, Ninomiya JK, Wingard DL, Ji M, Fronek A. Progression of peripheral arterial disease predicts cardiovascular disease morbidity and mortality. J Am Coll Cardiol 2008;52:1736-42.

**\[14\]**: Aboyans V, Ricco JB, Bartelink MEL, Björck M, Brodmann M, Cohnert T, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 2018;55:305-68.

**\[15\]**: Frank U, Nikol S, Belch J, Boc V, Brodmann M, Carpentier PH, et al. European Society of Vascular Medicine (ESVM). Guideline on peripheral arterial disease. Vasa 2019;48 Suppl 102:1-79.

**\[16\]**: Pande RL, Perlstein TS, Beckman JA, Creager MA. Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004. Circulation. 2011;124:17–23.

**\[17\]**: Hess CN, Rogers RK, Wang TY, Fu R, Gundrum J, Allen LaPointe NM, Hiatt WR. Major adverse limb events and 1-year outcomes after peripheral artery revascularization. J Am Coll Cardiol. 2018;72:999–1011.

**\[18\]**: Criqui MH, Matsushita K, Aboyans V, Hess CN, Hicks CW, Kwan TW, et al. Lower extremity peripheral artery disease: Contemporary epidemiology, management gaps, and future directions. A scientific statement from the American Heart Association. Circulation 2021;144:e171–e191.

**\[19\]**: Frank U, Nikol S, Belch J, Boc V, Brodmann M, Carpentier PH, et al. European Society of Vascular Medicine (ESVM). Guideline on peripheral arterial disease. Vasa 2019;48 Suppl 102:1-79.

**\[20\]**: Wang Y, Wu X, Hu X, Yang Y. Prevalence of frailty in patients with lower extremity peripheral arterial disease: A systematic review and meta-analysis. Ageing Res Rev. 2022 Oct 7;82:101748.

**\[21\]**: Pandit V, Tan T-W, Kempe K, Chitwood J, Kim H, Horst V, Zhou W, Nelson P. Frailty Syndrome in Patients With Lower Extremity Amputation: Simplifying How We Calculate Frailty. J Surg Res. 2021 Jul;263:230-235.

**\[22\]**: Sandvik H, Hetlevik Ø, Blinkenberg J, Hunskaar S. Continuity in general practice as predictor of mortality, acute hospitalisation, and use of out-of-hours care: a registry-based observational study in Norway. Br J Gen Pract. 2022 Jan 27;72(715):e84-e90.

**\[23\]**: Aboyans V, Ricco JB, Bartelink MEL, Björck M, Brodmann M, Cohnert T, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 2018;55:305-68.

**\[24\]**: Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135(12):e726-e79

**\[25\]**: Aboyans V, Criqui MH, Abraham P, Allison MA, Creager MA, Diehm C, et al. Measurement and Interpretation of the Ankle-Brachial Index. Circulation. 2012;126(24):2890-909.

**\[26\]**: Aboyans V, Ricco JB, Bartelink MEL, Björck M, Brodmann M, Cohnert T, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 2018;55:305-68.

**\[27\]**: Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010;303:841-8.

**\[28\]**: Belch JJ; Dormandy J, Biasi GM, Cairols M, Diehm C, Eikelboom B, et al, CASPAR Writing Committee. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease. J Vasc Surg 2010;52:825-33.

**\[29\]**: Frank U, Nikol S, Belch J, Boc V, Brodmann M, Carpentier PH, et al. European Society of Vascular Medicine (ESVM). Guideline on peripheral arterial disease. Vasa 2019;48 Suppl 102:1-79.

**\[30\]**: Aboyans V, Ricco JB, Bartelink MEL, Björck M, Brodmann M, Cohnert T, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 2018;55:305-68.

**\[31\]**: Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71-86.

**\[32\]**: CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.

**\[33\]**: Katsanos K, Spiliopoulos S, Saha P, Diamantopoulos A, Karunanithy N, Krokidis M, et al. Comparative efficacy and safety of different antiplatelet agents for prevention of major cardiovascular events and leg amputations in patients with peripheral arterial disease: a systematic review and network meta-analysis. PLoS One 2015;10:e0135692.

**\[34\]**: Frank U, Nikol S, Belch J, Boc V, Brodmann M, Carpentier PH, et al. European Society of Vascular Medicine (ESVM). Guideline on peripheral arterial disease. Vasa 2019;48 Suppl 102:1-79.

**\[35\]**: Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR,  Hart RG, Shestakovska O, et al; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017; 377:1319-30.

**\[36\]**: Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, et al on behalf of the COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018;391:219-29.

**\[37\]**: Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, et al: GVG Writing Group for the Joint Guidelines of the Society for Vascular Surgery (SVS), European Society for Vascular Surgery (ESVS), and World Federation of Vascular Societies (WFVS). Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. Eur J Vasc Endovasc Surg 2019;58, S1eS109.

**\[38\]**: Eikelboom JW, Bhatt DL, Fox KAA, Bosch J, Connolly SJ, Anand SS, et al. Mortality benefit of rivaroxaban plus aspirin in patients with chronic coronary or peripheral artery disease J Am Coll Cardiol 2021;78:14-23.

**\[39\]**: Frank U, Nikol S, Belch J, Boc V, Brodmann M, Carpentier PH, et al. European Society of Vascular Medicine (ESVM). Guideline on peripheral arterial disease. Vasa 2019;48 Suppl 102:1-79.

**\[40\]**: Aboyans V, Ricco JB, Bartelink MEL, Björck M, Brodmann M, Cohnert T, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 2018;55:305-68.

**\[41\]**: Peeters Weem SMO, van Haelst STW, den Ruijter HM, Moll FL, de Borst GJ. Lack of Evidence for Dual Antiplatelet Therapy after Endovascular Arterial Procedures: A Meta-analysis. Eur J Vasc Endovasc Surg 2016;52:253-62.

**\[42\]**: Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med 2020;382:1994-2000.

**\[43\]**: Hiatt WR, Bonaca MP, Patel MR, Nehler MR, Debus ES, Anand SS, et al. Rivaroxaban and aspirin in peripheral artery disease lower extremity revascularization. Impact of concomitant clopidogrel on efficacy and safety. Circulation 2020;142:2219-30.

**\[44\]**: Belch JJ; Dormandy J, Biasi GM, Cairols M, Diehm C, Eikelboom B, et al, CASPAR Writing Committee. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease. J Vasc Surg 2010;52:825-33.

**\[45\]**: Menke J, Lüthje L, Kastrup A, Larsen J. Thromboembolism in atrial fibrillation. Am J Cardiol 2010; 105:502e10. Wasilewska M, Gosk-Bierska I. Thromboembolism associated with atrial fibrillation as a cause of limb and organ ischemia. Adv Clin Exp Med 2013;22:865e73.

**\[46\]**: Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood 2018;132:1365-71.

**\[47\]**: Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013;369:1206-14.

**\[48\]**: Lee HF, Chan YH, Li PR, Liu JR, Chao TF, Wu LS, et al. Oral anticoagulants and antiplatelet agents in patients with atrial fibrillation and concomitant critical limb ischemia: A nationwide cohort study. Can J Cardiol 2021;37:113-21.

**\[49\]**: De Haro J, S Bleda S, C Varela C, C Cañibano C, F Acin F. Meta-analysis and adjusted indirect comparison of direct oral anticoagulants in prevention of acute limb ischemia in patients with atrial fibrillation. Curr Med Res Opin 2016;32:1167-73.

**\[50\]**: Frost L, Engholm G, Johnsen S, Moller H, Henneberg EW, Husted S. Incident thromboembolism in the aorta and the renal, mesenteric, pelvic, and extremity arteries after discharge from the hospital with a diagnosis of atrial fibrillation. Arch Intern Med 2001;161:272–6.

**\[51\]**: Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42:373-498.

**\[52\]**: Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955-62.

**\[53\]**: Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92.

**\[54\]**: Geller BJ, Giugliano RP, Braunwald E, Murphy SA, Hanyok JJ, Jin J, et al. Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial. Am Heart J 2015;170:669-74.

**\[55\]**: Patel MR, Mahaffey KW, Garg J, Guohua Pan G, Daniel E Singer DE, Werner Hacke W, et al, ROCKET AF Investigators. Rivaroxaban vs.warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.

**\[56\]**: Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51

**\[57\]**: Geraghty AJ, Welch K. Antithrombotic agents for preventing thrombosis after infrainguinal arterial bypass surgery. Cochrane Database Syst Rev 2011;6:CD000536.

**\[58\]**: Strobl FF, Brechtel K, Schmehl J, Zeller T, Reiser MF, Claussen CD, et. al. Twelve-month results of a randomized trial comparing mono with dual antiplatelet therapy in endovascularly treated patients with peripheral artery disease. J Endovasc Ther 2013;20:699-706.

**\[59\]**: Tepe G, Bantleon R, Brechtel K, Schmehl J, Zeller T, Claussen CD, et. al. Management of peripheral arterial interventions with mono or dual antiplatelet therapy–the MIRROR study: a randomised and double blinded clinical trial. Eur Radiol 2012;22:1998-2006.

**\[60\]**: Cacoub PP, Bhatt DP, Steg PG, Topol EJ, Creager MA. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J 2009;30:192-201.

**\[61\]**: Hiatt WR, Fowkes FGR, Heizer G, Berger JS, Baumgartner I, Held P, et al, for the EUCLID trial steering committee and investigators. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med 2017;376:32-40.

**\[62\]**: Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008;337:a1840.

**\[63\]**: Lee HF, Chan YH, Li PR, Liu JR, Chao TF, Wu LS, et al. Oral anticoagulants and antiplatelet agents in patients with atrial fibrillation and concomitant critical limb ischemia: A nationwide cohort study. Can J Cardiol 2021;37:113-21.

**\[64\]**: De Haro J, S Bleda S, C Varela C, C Cañibano C, F Acin F. Meta-analysis and adjusted indirect comparison of direct oral anticoagulants in prevention of acute limb ischemia in patients with atrial fibrillation. Curr Med Res Opin 2016;32:1167-73.

**\[65\]**: Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42:373-498.

**\[66\]**: Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med 2020;382:1994-2000.

**\[67\]**: Peeters Weem SMO, van Haelst STW, den Ruijter HM, Moll FL, de Borst GJ. Lack of Evidence for Dual Antiplatelet Therapy after Endovascular Arterial Procedures: A Meta-analysis. Eur J Vasc Endovasc Surg 2016;52:253-62.

**\[68\]**: Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, et al: GVG Writing Group for the Joint Guidelines of the Society for Vascular Surgery (SVS), European Society for Vascular Surgery (ESVS), and World Federation of Vascular Societies (WFVS). Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. Eur J Vasc Endovasc Surg 2019;58, S1eS109.

**\[69\]**: Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, et al on behalf of the COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018;391:219-29.

**\[70\]**: Aboyans V, Ricco JB, Bartelink MEL, Björck M, Brodmann M, Cohnert T, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 2018;55:305-68.

**\[71\]**: Katsanos K, Spiliopoulos S, Saha P, Diamantopoulos A, Karunanithy N, Krokidis M, et al. Comparative efficacy and safety of different antiplatelet agents for prevention of major cardiovascular events and leg amputations in patients with peripheral arterial disease: a systematic review and network meta-analysis. PLoS One 2015;10:e0135692.

**\[72\]**: CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.

**\[73\]**: Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71-86.

**\[74\]**: Belch JJ; Dormandy J, Biasi GM, Cairols M, Diehm C, Eikelboom B, et al, CASPAR Writing Committee. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease. J Vasc Surg 2010;52:825-33.

**\[75\]**: Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010;303:841-8.

**\[76\]**: Frank U, Nikol S, Belch J, Boc V, Brodmann M, Carpentier PH, et al. European Society of Vascular Medicine (ESVM). Guideline on peripheral arterial disease. Vasa 2019;48 Suppl 102:1-79.

**\[77\]**: Twine CP, Kakkos SK, Aboyans V, Baumgartner I, Behrendt CA, et al. European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on Antithrombotic Therapy for Vascular Diseases. Eur J Vasc Endovasc Surg. 2023;65:627-689

**\[78\]**: Nordanstig J, Behrendt C-A, Baumgartner I, Belch J, Bäck M, Fitridge R, Hinchliffe R, Lejay A, Mills JL, Rother U, Sigvant B, Spanos K, Szeberin Z, van de Water W. European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Asymptomatic Lower Limb Peripheral Arterial Disease and Intermittent Claudication. Eur J Vasc Endovasc Surg 2024; 67, 9e96.

**\[79\]**: Visseren FL, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida J-M, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C, Williams B, ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227–3337.

**\[80\]**: Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith Jr SC, Goto S, Ohman EM, Elbez Y, Sritara P, Baumgartner I, Banerjee S, Creager MA, Bhatt DL, REACH Registry Investigators. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J . 2014 Nov 1;35(41):2864-72. doi: 10.1093/eurheartj/ehu080.

**\[81\]**: Momsen AH, Jensen MB, Norager CB, Madsen MR, Vestersgaard-Andersen T, Lindholt JS. Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies. Eur J Vasc Endovasc Surg. 2009 Oct;38(4):463-74. doi: 10.1016/j.ejvs.2009.06.002.

**\[82\]**: Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen M-R, Tokgozoglu L, Wiklund O, ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-188.

**\[83\]**: Visseren FL, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida J-M, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C, Williams B, ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227–3337.

**\[84\]**: Paravastu SCV, Mendonca DA, Da Silva A. Beta blockers for peripheral arterial disease. Cochrane Database Syst Rev. 2013 Sep 11;2013(9):CD005508.

**\[85\]**: Visseren FL, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida J-M, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C, Williams B, ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227–3337.

**\[86\]**: Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, Muiesan ML, Tsioufis K, Agabiti-Rosei E, Algharably EAE, Azizi M, Benetos A, Borghi C, Hitij JB, Cifkova R, Coca A, Cornelissen V, Cruickshank JK, Cunha PG, Danser AHJ, Pinho RM, Delles C, Dominiczak AF, Dorobantu M, Doumas M, Fernández-Alfonso MS, Halimi JM, Járai Z, Jelaković B, Jordan J, Kuznetsova T, Laurent S, Lovic D, Lurbe E, Mahfoud F, Manolis A, Miglinas M, Narkiewicz K, Niiranen T, Palatini P, Parati G, Pathak A, Persu A, Polonia J, Redon J, Sarafidis P, Schmieder R, Spronck B, Stabouli S, Stergiou G, Taddei S, Thomopoulos C, Tomaszewski M, Van de Borne P, Wanner C, Weber T, Williams B, Zhang ZY, Kjeldsen SE. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens 2023; 41:1874–2071.

**\[87\]**: Singh S, Armstrong EJ, Sherif W, Alvandi B, Westin GG, Singh GD, Amsterdam EA, Laird JR. Association of elevated fasting glucose with lower patency and increased major adverse limb events among patients with diabetes undergoing infrapopliteal balloon angioplasty. Vasc Med. 2014 Aug;19(4):307-314. doi: 10.1177/1358863X14538330.

**\[88\]**: Visseren FL, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida J-M, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C, Williams B, ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227–3337.

**\[89\]**: Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, Christodorescu RM, Crawford C, Di Angelantonio E, Eliasson B, Espinola-Klein C, Fauchier L, Halle M, Herrington WG, Kautzky-Willer A, Lambrinou E, Lesiak M, Lettino M, McGuire DK, Mullens W, Rocca B, Sattar N, ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). Eur Heart J, Volume 44, Issue 39, 14 October 2023, Pages 4043–4140.

**\[90\]**: Marchiori E, Rodionov RN, Peters F, Magnussen C, Nordanstig J, Gombert A et al. SGLT2 Inhibitors and Peripheral Vascular Events: A Review of the Literature. Heart Fail Clin. 2022 Oct;18(4):609-623.

**\[91\]**: Lin C, Zhu X, Cai X, Yang W, Lv F, Nie L, Ji L. SGLT2 inhibitors and lower limb complications: an updated meta-analysis. Cardiovasc Diabetol. 2021 Apr 28;20(1):91. doi: 10.1186/s12933-021-01276-9

**\[92\]**: Visseren FL, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida J-M, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C, Williams B, ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227–3337.

**\[93\]**: Visseren FL, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida J-M, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C, Williams B, ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227–3337.

**\[94\]**: Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, Rosas SE, Del Prato S, Mathieu C, Mingrone G, Rossing P, Tankova T, Tsapas A, Buse JB. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022 Sep 24;1-42.

**\[95\]**: Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri TV, Johansson I, Jüni P, Lettino M, Marx N, Mellbin LG, Östgren CJ, Rocca B, Roffi M, Sattar N, Seferović PM, Sousa-Uva M, Valensi P, Wheeler DC, ESC Scientific Document Group2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020 Jan 7;41(2):255-323. doi: 10.1093/eurheartj/ehz486.

**\[96\]**: Visseren FL, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida J-M, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C, Williams B, ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227–3337.

**\[97\]**: Haile S, Lööf H, Johansson UB, Linné A, Joelsson-Alm E. Increasing patients' awareness of their own health: Experiences of participating in follow-up programs after surgical treatment for intermittent claudication. J Vasc Nurs. 2022 Mar;40(1):47-53. doi: 10.1016/j.jvn.2021.11.004. Epub 2021 Dec 21. PMID: 35287834.

**\[98\]**: Siercke M, Berg SK, Missel M. Spurred by pedometers, unity and fun exercise: A qualitative study of participation in rehabilitation for patients with intermittent claudication (The CIPIC Rehab study). J Vasc Nurs. 2021 Sep;39(3):59-66. doi: 10.1016/j.jvn.2021.06.001. Epub 2021 Jun 29. PMID: 34507702.

**\[99\]**: Parmenter BJ, Dieberg G, Smart NA. Exercise training for management of peripheral arterial disease: a systematic review and meta-analysis. Sports Medicine. 2015;45(2):231-44.

**\[100\]**: Fokkenrood HJ, Bendermacher BL, Lauret GJ, Willigendael EM, Prins MH, Teijink JA. Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication. Cochrane Database of Systematic Reviews. 2013(8):CD005263.

**\[101\]**: Hageman D, Fokkenrood HJ, Gommans LN, van den Houten MM, Teijink JA. Supervised exercise therapy versus home-based exercise therapy versus walking advice for intermittent claudication. Cochrane Database of Systematic Reviews. 2018;4:CD005263.

**\[102\]**: Vemulapalli S, Dolor RJ, Hasselblad V, Schmit K, Banks A, Heidenfelder B, et al. Supervised vs unsupervised exercise for intermittent claudication: A systematic review and meta-analysis. Am Heart J. 2015;169(6):924-37.e3.

**\[103\]**: Parmenter BJ, Dieberg G, Phipps G, Smart NA. Exercise training for health-related quality of life in peripheral artery disease: a systematic review and meta-analysis. Vascular medicine. 2015;20(1):30-40.

**\[104\]**: Djerf H, Millinger J, Falkenberg M, Jivegård L, Svensson M, Nordanstig J. Absence of Long-Term Benefit of Revascularization in Patients With Intermittent Claudication: Five-Year Results From the IRONIC Randomized Controlled Trial. Circ Cardiovasc Interv. 2020 Jan;13(1):e008450)

**\[105\]**: Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, Fleisher LA, Fowkes FG, Hamburg NM, Kinlay S, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e726–e779.

**\[106\]**: Ambrosetti M, Abreu A, Corrà U, et al. Secondary prevention through comprehensive cardiovascular rehabilitation: From knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. Eur J Prev Cardiol. 2020:2047487320913379.

**\[107\]**: Parmenter BJ, Dieberg G, Smart NA. Exercise training for management of peripheral arterial disease: a systematic review and meta-analysis. Sports Medicine. 2015;45(2):231-44.

**\[108\]**: Fokkenrood HJ, Bendermacher BL, Lauret GJ, Willigendael EM, Prins MH, Teijink JA. Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication. Cochrane Database of Systematic Reviews. 2013(8):CD005263.

**\[109\]**: Hageman D, Fokkenrood HJ, Gommans LN, van den Houten MM, Teijink JA. Supervised exercise therapy versus home-based exercise therapy versus walking advice for intermittent claudication. Cochrane Database of Systematic Reviews. 2018;4:CD005263.

**\[110\]**: Vemulapalli S, Dolor RJ, Hasselblad V, Schmit K, Banks A, Heidenfelder B, et al. Supervised vs unsupervised exercise for intermittent claudication: A systematic review and meta-analysis. Am Heart J. 2015;169(6):924-37.e3.

**\[111\]**: Golledge J, Singh TP, Alahakoon C, Pinchbeck J, Yip L, Moxon JV, et al. Meta-analysis of clinical trials examining the benefit of structured home exercise in patients with peripheral artery disease. BJS. 2019;106(4):319-31.

**\[112\]**: Saratzis A, Paraskevopoulos I, Patel S, Donati T, Biasi L, Diamantopoulos A, et al. Supervised Exercise Therapy and Revascularization for Intermittent Claudication: Network Meta-Analysis of Randomized Controlled Trials. JACC Cardiovasc Interv. 2019;12(12):1125-36.

**\[113\]**: Klaphake S, Buettner S, Ultee KH, van Rijn MJ, Hoeks SE, Verhagen HJ. Combination of endovascular revascularization and supervised exercise therapy for intermittent claudication: a systematic review and meta-analysis. J Cardiovasc Surg. 2018;59(2):150-7.

**\[114\]**: Meneses AL, Ritti-Dias RM, Parmenter B, Golledge J, Askew CD. Combined Lower Limb Revascularisation and Supervised Exercise Training for Patients with Peripheral Arterial Disease: A Systematic Review of Randomised Controlled Trials. Sports Med. 2017;47(5):987-1002.

**\[115\]**: Vemulapalli S. Revascularisation plus supervised exercise is superior to supervised exercise alone for the treatment of intermittent claudication. Evidence-based medicine. 2016;21(3):91.

**\[116\]**: Fakhry F, Fokkenrood HJ, Spronk S, Teijink JA, Rouwet EV, Hunink MGM. Endovascular revascularisation versus conservative management for intermittent claudication. Cochrane Database Syst Rev. 2018;3:CD010512.

**\[117\]**: Doshi R, Shah P, Majmundar M, Kumar A, Vallabhajosyula S. Comparison of supervised exercise therapy with or without revascularization for the management of intermittent claudication: SET in PAD. European journal of internal medicine. 2021;92:131-3.

**\[118\]**: Smolderen KG, Samaan Z, Decker C, Collins T, Lazar RM, Itoga NK, Mena-Hurtado C; American Heart Association Council on Peripheral Vascular Disease; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Lifestyle and Cardiometabolic Health; and Council on Quality of Care and Outcomes Research. Association Between Mental Health Burden, Clinical Presentation, and Outcomes in Individuals With Symptomatic Peripheral Artery Disease: A Scientific Statement From the American Heart Association. Circulation. 2023 Nov 7;148(19):1511-1528.

**\[119\]**: Smolderen KG, Buchanan DM, Amin AA, Gosch K, Nugent K, Riggs L, Seavey G, Spertus JA. Real-world lessons from the implementation of a depression screening protocol in acute myocardial infarction patients: implications for the American Heart Association depression screening advisory. Circ Cardiovasc Qual Outcomes. 2011 May;4(3):283-92.

**\[120\]**: Thomas S, Jenkins R, Burch T, Calamos Nasir L, Fisher B, Giotaki G, Gnani S, Hertel L, Marks M, Mathers N, Millington-Sanders C, Morris D, Ruprah-Shah B, Stange K, Thomas P, White R, Wright F. Promoting Mental Health and Preventing Mental Illness in General Practice. London J Prim Care (Abingdon). 2016 Feb 24;8(1):3-9.

**\[121\]**: Yazgan I, Bartlett V, Romain G, Cleman J, Petersen-Crair P, Spertus JA, Hardt M, Mena-Hurtado C, Smolderen KG. Longitudinal Pathways Between Physical Activity, Depression, and Perceived Stress in Peripheral Artery Disease. Circ Cardiovasc Qual Outcomes. 2023 Aug;16(8):544-553.

**\[122\]**: Visseren FL, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida J-M, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C, Williams B, ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227–3337.

**\[123\]**: Lu L, Mackay DF, Pell JP. Meta-analysis of the association between cigarette smoking and peripheral arterial disease. Heart. 2014;100:414–423.

**\[124\]**: Song P, Rudan D, Zhu Y, Fowkes FJ, Rahimi K, Fowkes FG, Rudan I. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: An updated systematic review and analysis. Lancet Glob. Health. 2019;7:e1020–e1030.

**\[125\]**: Visseren FL, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida J-M, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C, Williams B, ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227–3337.

**\[126\]**: Delgado-Lista J, Alcala-Diaz JF, Torres-Peña JD, Quintana-Navarro GM, Fuentes F, Garcia-Rios A, Ortiz-Morales AM, Gonzalez-Requero AI, Perez-Caballero AI, Yubero-Serrano EM, Rangel-Zuñiga OA, Camargo A, Rodriguez-Cantalejo F, Lopez-Segura F, Badimon L, Ordovas JM, Perez-Jimenez F, Perez-Martinez P, Lopez-Miranda J, CORDIOPREV Investigators. Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. Lancet. 2022 May 14;399(10338):1876-1885.

**\[127\]**: Visseren FL, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida J-M, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C, Williams B, ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227–3337.

**\[128\]**: Wood AM, Kaptoge S, Butterworth AS, Willeit P, Warnakula S, Bolton T et al. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. Lancet. 2018 Apr 14;391(10129):1513-1523.

**\[129\]**: Larsson SC, Burgess S, Mason AM, Michaelsson K. Alcohol Consumption and Cardiovascular Disease: A Mendelian Randomization Study. Circ Genom Precis Med. 2020 Jun;13(3):e002814.

**\[130\]**: Visseren FL, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida J-M, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C, Williams B, ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227–3337.

**\[131\]**: Rodighiero J, Léveillé N, Shen S, Ekmekjian T, Ades M, Drudi LM. A scoping review of malnutrition in patients undergoing interventions for peripheral arterial disease. J Vasc Surg. 2022 Jun 14;S0741-5214(22)01625-1.

**\[132\]**: Aboyans V, Ricco JB, Bartelink MEL, Björck M, Brodmann M, Cohnert T, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 2018;55:305-68.

**\[133\]**: Socialstyrelsen. Nationella riktlinjer för prevention och behandling vid ohälsosamma levnadsvanor. Stöd för styrning och ledning. Stockholm: Socialstyrelsen; 2018.

**\[134\]**: Sandvik H, Hetlevik Ø, Blinkenberg J, Hunskaar S. Continuity in general practice as predictor of mortality, acute hospitalisation, and use of out-of-hours care: a registry-based observational study in Norway. Br J Gen Pract. 2022 Jan 27;72(715):e84-e90.

**\[135\]**: Haile ST, Joelsson-Alm E, Johansson UB, Lööf H, Palmer-Kazen U, Gillgren P, Linné A. Effects of a person-centred, nurse-led follow-up programme on adherence to prescribed medication among patients surgically treated for intermittent claudication: randomized clinical trial. Br J Surg. 2022 Aug 16;109(9):846-856. doi: 10.1093/bjs/znac241. PMID: 35848783

**\[136\]**: Murchie P, Campbell NC, Ritchie LD, Simpson JA, Thain J. Secondary prevention clinics for coronary heart disease: four year follow up of a randomised controlled trial in primary care. J.BMJ.2003;326:84.

**\[137\]**: Gluyas H. Patient-centred care: improving healthcare outcomes. Nurs Stand. 2015 Sep 23;30(4):50-7

**\[138\]**: Flynn D, Knoedler MA, Hess EP, Hassan Murad M, Erwin PJ, Montori VM, Thomson RG. Engaging patients in health care decisions in the emergency department through shared decision-making: a systematic review. Acad Emerg Med. 2012 Aug;19(8):959-67.

**\[139\]**: Hirpa M, Woreta T, Addis H, Kebede S. What matters to patients? A timely question for value-based care. PLoS One. 2020 Jul 9;15(7):e0227845.

**\[140\]**: Ebrahimi Z, Patel H, Wijk H, Ekman I, Olaya-Contreras P. A systematic review on implementation of person-centered care interventions for older people in out-of-hospital settings. Geriatr Nurs. 2021 Jan-Feb;42(1):213-224.
